Our findings underscore the emerging role of postoperative immunotherapy as an independent predictor of longer OS and showed a favorable trend for improved iPFS, reinforcing data that immune-based therapies substantially contribute to both systemic and intracranial disease control in NSCLC-BM [ 29 , 30 ].
← all excerpts
Postoperative absence of residual intracranial tumor volume is associated with improved survival and intracranial disease control in non-small cell lung cancer brain metastases.
1
—
—